Lexaria Bioscience Company Insiders
| LEXXW Stock | USD 0.80 0.05 6.67% |
Lexaria Bioscience employs about 5 people. The company is managed by 11 executives with a total tenure of roughly 12 years, averaging almost 1.0 years of service per executive, having 0.45 employees per reported executive. Recap of Lexaria Bioscience's management performance can provide insight into the venture performance.
Lexaria |
Lexaria Bioscience Management Team Effectiveness
The company has return on total asset (ROA) of (0.3821) % which means that it has lost $0.3821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7066) %, meaning that it generated substantial loss on money invested by shareholders. Lexaria Bioscience's management efficiency ratios could be used to measure how well Lexaria Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to climb to 0.14 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.52). At this time, Lexaria Bioscience's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 1.3 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.52).Common Stock Shares Outstanding is likely to climb to about 13 M in 2024, whereas Net Loss is likely to drop (3.7 M) in 2024.
Lexaria Bioscience Workforce Comparison
Lexaria Bioscience Corp is rated fifth overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 587. Lexaria Bioscience maintains roughly 5.0 in number of employees contributing less than 1% to equities under Health Care industry.
Lexaria Bioscience Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lexaria Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lexaria Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lexaria Bioscience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lexaria Bioscience Notable Stakeholders
A Lexaria Bioscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lexaria Bioscience often face trade-offs trying to please all of them. Lexaria Bioscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lexaria Bioscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John MSc | President Director | Profile | |
| Kristin Hamilton | Director Operations | Profile | |
| Christopher Bunka | Chairman CEO | Profile | |
| Vanessa Carle | Head Legal | Profile | |
| Philip Ainslie | Advisor Consultant | Profile | |
| Nelson CPA | Chief Officer | Profile | |
| Richard Christopher | Chief Officer | Profile | |
| Michael CPA | Chief Officer | Profile | |
| Michael Shankman | Chief Officer | Profile | |
| John Docherty | Pres Director | Profile | |
| Mike Shankman | Chief Officer | Profile |
About Lexaria Bioscience Management Performance
The success or failure of an entity such as Lexaria Bioscience Corp often depends on how effective the management is. Lexaria Bioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lexaria management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lexaria management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.52) | |
| Return On Capital Employed | (0.74) | 0.14 | |
| Return On Assets | (0.65) | (0.52) | |
| Return On Equity | (0.72) | (0.89) |
Please note, the imprecision that can be found in Lexaria Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lexaria Bioscience Corp. Check Lexaria Bioscience's Beneish M Score to see the likelihood of Lexaria Bioscience's management manipulating its earnings.
Lexaria Bioscience Workforce Analysis
Traditionally, organizations such as Lexaria Bioscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lexaria Bioscience within its industry.Lexaria Bioscience Manpower Efficiency
Return on Lexaria Bioscience Manpower
| Revenue Per Employee | 92.9K | |
| Revenue Per Executive | 42.2K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 528.1K | |
| Working Capital Per Employee | 386.4K | |
| Working Capital Per Executive | 175.6K |
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.